Craft

Theravance Biopharma

Stock Price

$8.6

2024-10-29

Market Capitalization

$429 M

2024-10-29

Revenue

$107.5 M

FY, 2025

Theravance Biopharma Summary

Company Summary

Overview
Theravance Biopharma is a biopharmaceutical company which provides medicines to treat serious illnesses. It focuses on several therapeutic areas, including infectious disease, respiratory, gastrointestinal disease, and cardiovascular and renal disease.
Type
Public
Status
Active
Founded
1996
HQ
Dublin, IE | view all locations
Website
http://www.theravance.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Rick E. Winningham

    Rick E. Winningham, Chairman, Chief Executive Officer

  • Eran Broshy, Director

    • Reigin Zawadzki

      Reigin Zawadzki, Vice President, Human Resources

    • Rhonda F. Farnum

      Rhonda F. Farnum, Senior Vice President, Commercial and Medical Affairs

      Operating MetricsView all

      Patents (Foreign)

      1.7K
      14.7%

      FY, 2018

      Patents (US)

      438
      4.6%

      FY, 2018

      Partners

      6

      Apr, 2019

      LocationsView all

      2 locations detected

      • Dublin, County Dublin HQ

        Ireland

        Connaught House, 1 Burlington Rd

      • San Francisco, CA

        United States

        901 Gateway Boulevard

      Theravance Biopharma Financials

      Summary Financials

      Revenue (FY, 2025)
      $107.5M
      Gross profit (FY, 2025)
      $107.5M
      Net income (FY, 2025)
      $105.9M
      Cash (FY, 2025)
      $167.8M
      EBIT (FY, 2025)
      $121.5M

      Footer menu